aTyr Pharma to Present at Upcoming Investor Conferences
SAN DIEGO, May 20, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer, will present at several upcoming investor conferences scheduled to take place in May and June 2025.
Details of the conferences appear below:
Conference: RBC Capital Markets Global Healthcare Conference
Date: Wednesday, May 21, 2025
Time: 11:00am EDT
Location: New York, NY
Format: Fireside Chat
Conference: Piper Sandler 3rd Annual Virtual Lung Symposium with ATS Takeaways
Date: Tuesday, May 27, 2025
Time: 2:00pm EDT
Location: Virtual
Format: Fireside Chat
Conference: Jefferies Global Healthcare Conference
Date: Thursday, June 5, 2025
Time: 2:00pm EDT
Location: New York, NY
Format: Fireside Chat
In addition to the presentations, company management will be available to participate in one-on-one meetings with investors who are registered attendees of the RBC and Jefferies conferences. A webcast of the RBC and Jefferies events will be available on the Investor’s section of the company’s website at . Following the events, a replay of the RBC and Jefferies presentations will be available on the aTyr website for at least 90 days. For more information, contact .
About aTyr
aTyr is a clinical stage biotechnology company leveraging evolutionary intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation. tRNA synthetases are ancient, essential proteins that have evolved novel domains that regulate diverse pathways extracellularly in humans. aTyr’s discovery platform is focused on unlocking hidden therapeutic intervention points by uncovering signaling pathways driven by its proprietary library of domains derived from all 20 tRNA synthetases. aTyr’s lead therapeutic candidate is efzofitimod, a first-in-class biologic immunomodulator in clinical development for the treatment of interstitial lung disease, a group of immune-mediated disorders that can cause inflammation and progressive fibrosis, or scarring, of the lungs. For more information, please visit .
| Contact: | |
| Ashlee Dunston | |
| Sr. Director, Investor Relations and Public Affairs | |
